Rheumatoid is rheumatoid arthritis. With the advancement of technology, biologics are now the new technology in modern medicine to control rheumatoid.
The goal of treating rheumatoid arthritis is to minimize swelling and pain in the patient’s joints, prevent joint deformity, and help maintain normal motor function. Rheumatoid diseases mainly rely on traditional anti-rheumatic drugs such as methotrexate and leflunomide.
However, with the development of modern medical science and technology, new technologies have emerged in recent years, mainly the use of biologics, which have significantly improved the prognosis of rheumatoid arthritis.
Biological agents mainly include anti-tumor necrosis factor inhibitors (e.g., infliximab, etanercept, etc.), interleukin-6 inhibitors (e.g., tolizumab, etc.), rituximab, abatacept, tofacitib, etc., whose strength of action is many times higher than that of traditional drugs, and which can effectively prevent structural damage to joints.
However, biologics require injection administration, the drugs are expensive, and the risk of secondary infections, malignancies, etc. is slightly higher. Therefore, it is recommended that patients with rheumatoid arthritis consult the rheumatology and immunology department in a timely manner, and under the guidance of a professional doctor to carry out reasonable treatment. The use of the above drugs must be in accordance with the doctor’s instructions, to avoid the unauthorized use of drugs with adverse risks.